Equity Financial Planners Pty Ltd v AMP Financial Planning Pty Ltd

Link copied
Case Copied 84 min read

FEDERAL COURT OF AUSTRALIA

Equity Financial Planners Pty Ltd v AMP Financial Planning Pty Ltd [2024] FCA 1036

File number(s): VID 498 of 2020
Judgment of: MCELWAINE J
Date of judgment: 6 September 2024
Catchwords: REPRESENTATIVE PROCEEDINGS– application for approval of a settlement pursuant to s 33V(1) of the Federal Court of Australia Act 1976 (FCA Act)- where 20% of group members object- the importance of objections and the protective function of the Court explained- whether proposed settlement is fair and reasonable-consideration of proposed deductions from settlement sum- ATE insurance premiums and internal expenses disallowed- whether suppression and non-publication orders are necessary to prevent prejudice to the administration of justice-duration of orders- whether orders until further order comply with the requirement to fix a definite period at s 37AJ of the FCA Act-limited confidentiality orders made with variable duration periods- settlement with adjustments approved
Legislation:

Corporations Act 2001 (Cth)

Federal Court of Australia act 1976 (Cth) ss 33J(1), 33V, 33X, 33Y(2), 33ZB, 37AF, 37AG(1)(a)

Legal Profession Uniform Law, s 172

The Class Actions Practice Note (GPN-CA)

Cases cited:

Asirifi-Otchere v Swan Insurance (Aust) Pty Ltd (2020) 385 ALR 625

Blairgowrie Trading Ltd v AllcoFinance Group Ltd (Receivers and Managers Appointed) (in liq) (No 3) (2017) 343ALR 476

BMW Australia Ltd v Brewster (2019) 269 CLR 574

Bolitho v Banksia Securities Ltd (No 6) [2019] VSC 653

Botsman v Bolitho (No 1) [2018] VSCA 278

Bradshaw v BSA Ltd (No 2) [2022] FCA 1440

Camilleri v The Trust Company (Nominees) Ltd [2015] FCA 1468

Dyczynski v Gibson (2020) 280 FCR 583

Equity Financial Planners Pty Ltd v AMP Financial Planning Pty Ltd [2023] FCA 741

Equity Financial Planners Pty Ltd v AMP Financial Planning Pty Ltd (No 2) [2023] FCA 1033

Ewok Pty Ltd (Trustee) v Wellard Ltd [2024] FCA 296

Fordham v Commonwealth Bank of Australia Ltd [2023] FCA 1106

Fowkes v BostonScientific Corporation [2023] FCA 230

Galactic Seven Eleven Litigation Holdings LLC v Davaria (2024) 302 FCR 493

Ghee v BT Funds ManagementLtd [2023] FCA 1553

Inabu PtyLtd v Leighton Holdings Ltd [2014] FCA 622

Jenkins v Northern Territory of Australia (No 4) [2021] FCA 839

Kelly v Willmott Forests (in liq) (No 4) (2016) 335 ALR 439

Lee v Deputy Commissioner of Taxation (2023) 296 FCR 272

Luke v Aveo Group Ltd (No 3) [2023] FCA 1665

Motorola Solutions Inc v Hytera Communications CorporationLtd (No 2) [2018] FCA 17

Scott v Scott [1913] AC 417

Timbercorp Finance Pty Ltd (in liq)v Collins (2016) 259 CLR 212

Webb v GetSwift Ltd (No 7) (2023) 414 ALR 500

Wellesley v Duke of Beaufort (1827) 2 Russ 1

Division: General Division
Registry: Victoria
National Practice Area: Commercial and Corporations
Sub-area: Commercial Contracts, Banking, Finance and Insurance
Number of paragraphs: 194
Date of last submission/s: 4 September 2024
Date of hearing: 29-30 August 2024
Counsel for the Applicant   Mr R Craig KC with Mr R Rozenberg and Ms J Nikolic
Solicitor for the Applicant
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Equity Financial Planners Pty Ltd v AMP Financial Planning P... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCA 1036
Decision Date

CaseChat Overview and Summary

The proceeding in the Federal Court, Equity Financial Planners Pty Ltd v AMP Financial Planning Pty Ltd, involved a claim by Equity Financial Planners against AMP Financial Planning regarding changes to the valuation methodology under the BOLR Policy. The changes, made by AMPFP on 8 August 2019, reduced the multiples for valuing register rights and were contested by Equity. The court held that the changes were not authorised by the LEP Provision in the BOLR Policy and were therefore ineffective. The decision led to the approval of a settlement between the parties, with certain modifications. The court considered the objections of group members to the settlement, acknowledging their concerns but ultimately finding the settlement fair and reasonable. The court made orders approving the settlement, including the appointment of administrators and the distribution of funds, while also imposing confidentiality orders to protect sensitive information. The proceeding was dismissed without prejudice, allowing for potential future enforcement actions or claims by group members.

Orders

Orders of the court

1. Pursuant to s 33V of the Federal Court of Australia Act 1976 (Cth) (Act), the settlement of this proceeding (Settlement) be approved on the terms set out in:

(a) the Settlement Deed, being pages 4 to 36 to Confidential Exhibit CJP–1 of the Affidavit of Christopher John Pagent sworn 18 April 2024; and

(b) the Settlement Distribution Scheme, being pages 1 to 32 of Confidential Exhibit CJP–8 of the Affidavit of Christopher John Pagent sworn 26 June 2024 (Settlement Distribution Scheme).

2. Pursuant to s 33V of the Act, the Court authorises the Applicant nunc pro tunc on behalf of the Group Members (as defined in the Settlement Deed) (Group Members) to enter into and give effect to the Settlement Deed and the transactions contemplated thereby for and on behalf of the Group Members.

3. Pursuant to s 33ZB of the Act, the persons affected and bound by the Settlement are the Applicant, the Respondent, the Group Members and Augusta Pool 523 Limited (Funder).

Appointment of Administrator, Independent Barrister and Independent Senior Counsel

4. Pursuant to ss 33V and 33ZF of the Act, the Court appoints Mr Andrew Ross and Mr Ben Mahler of KordaMentha as the administrator of the Settlement Distribution Scheme (Administrator) to act in accordance with the Settlement Distribution Scheme and be given the powers and immunities contemplated by the Settlement Distribution Scheme.

5. The Administrator has liberty to apply in relation to any matter arising in relation to the Settlement Distribution Scheme.

6. Pursuant to ss 33V and 33ZF of the Act, the Court appoints Mr Peter Strickland and Ms Jane Buncle, each of counsel, as the Independent Barrister as defined in the Settlement Distribution Scheme, to perform the functions set out in the Settlement Distribution Scheme.

7. Pursuant to ss 33V and 33ZF of the Act, the Court appoints Mr Bernard Quinn KC as the Independent Senior Counsel as defined in the Settlement Distribution Scheme, to perform the functions set out in the Settlement Distribution Scheme.

Applicant and Sample Claimant Reimbursements

8. Pursuant to s 33V of the Act, the following payments be approved as, respectively, the Applicant’s Reimbursement and the Sample Claimant’s Reimbursement, as defined in the Settlement Distribution Scheme:

a. Applicant’s Reimbursement:

i. Ms Kylie Braschey ($30,000)

ii. Ms Leanne Scott ($30,000)

b. Sample Claimant’s Reimbursement – Mr Michael Finch ($20,000).

Approval of amounts to be deducted under the Settlement Distribution Scheme

9. Pursuant to section 33V(2) of the Act, the deductions from the Resolution Sum as outlined in the Settlement Distribution Scheme (updated as necessary to reflect the below deductions and figures) be approved, namely:

a. the “Funder Commission” totalling $26,578,805.83, to be paid to the Funder;

b. the “Applicant’s Paid Legal Costs” in the total amount of $10,573,022.33 (GST inclusive), to be paid to the Funder;

c. the “Applicant’s Unpaid Legal Costs” in the amount of $509,989.98 (GST inclusive), to be paid to the Applicant’s solicitors;

d. the “Applicant’s Future Legal Costs” in the amount of $1,009,926.02 (GST inclusive), to be paid to the Applicant’s solicitors;

e. a further amount in respect of the “Applicant’s Future Legal Costs” up to the amount of $195,800 (GST inclusive), subject to any further order varying that amount, to be paid to the Applicant’s solicitors;

f. the “Security Costs” in the amount of $360,259.96, to be paid to the Funder;

g. the “Applicant’s Reimbursement” as described in Order 8(a) above, to be paid to Ms Braschey and Ms Scott;

h. the “Sample Claimant’s Reimbursement” as described in Order 8(b) above, to be paid to Mr Finch;

i. the “Adverse Costs Order Reimbursement” in the amount of $58,500, to be paid to the Funder;

j. the “Contradictor’s Costs”, in the amount of up to $100,000.00, to be paid to the Contradictor and his junior, subject to any further order of the Court varying this amount;

k. the “Costs Referee’s Costs”, in the amount of $55,000 (GST inclusive), to be paid to the Costs Referee;

l. the “Administrator’s Costs” in the amount of $1,006,000.00, subject to any further order of the Court varying this amount;

Dismissal

10. Pursuant to ss 22, 23 or 33ZF of the Act or r 1.32 of the Federal Court Rules 2001 (Cth) (FCR) and/or the Court’s implied jurisdiction, and with effect from the date on which the final distribution of the Resolution Sum occurs under the Settlement Distribution Scheme, the proceeding against the Respondent be dismissed:

a. in accordance with the Settlement Deed, without prejudice to:

i. the right of any party to the Settlement Deed to make an application to enforce the Settlement Deed in a new proceeding;

ii. the right of any Group Member to make an application to the Court in accordance with the terms of the Settlement Distribution Scheme; and

iii. the right of the Administrator to refer any issues relating to the Settlement Distribution Scheme to the Court for direction or determination in accordance with the terms of the Settlement Distribution Scheme; and

b. on the basis that there be no order as to costs as between the Applicant and the Respondent and all previous costs orders in the proceeding between them are vacated.

Security for costs

11. All orders requiring the Applicant to provide security for costs are vacated and the security provided by the Funder, pursuant to orders made on 15 December 2020 and 1 June 2022, be paid to the Administrator.

Funding equalisation

12. Pursuant to s 33V and/or s 33ZF of the Act, the Funder Commission payable to the Funder by the Applicant and those Group Members who have entered into a litigation funding agreement with the Funder be apportioned on a pro rata basis between all Group Members and deducted from the Resolution Sum payable to all Group Members.

Confidentiality and undertakings

13. Pursuant to ss 37AF and 37AG(1)(a) of the Act, to prevent prejudice to the proper administration of justice, the publication of each of the items listed in Annexure A to these orders (the Confidentiality Claims Schedule) be limited to the persons and, or alternatively, subject to the limitation identified.

14. The applicant is to file by 4 pm on 10 September 2024 two consolidated PDF versions of the documents in the Confidentiality Claims Schedule, with the authorised redactions where applicable, one version containing the documents prior to the expiry of the appeal period and the other thereafter.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Annexure A – Confidentiality Claims Schedule

Item

Document

Date

Section over which confidentiality is claimed

Accessible by

Duration

Category 1 Information: Information which the parties have agreed to keep confidential (only applies to the Settlement Deed as per ruling of McElwaine J).

1.

Affidavit of Christopher John Pagent

18 April 2024

The whole of the Settlement Deed and the whole of the executed copies of the Settlement Deed, executed by the Applicant AMPFP, Corrs and Augusta, contained in Confidential Exhibit CJP–1 at pages 4–164.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) Group Members (upon undertaking to maintain confidentiality); (e) the Contradictor; (f) the Funder; (g) the Funder’s legal representatives; (h) the Respondent; and (i) the Respondent’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Until approval of the settlement

Category 2 Information: Information which discloses the proposed distribution the Settlement Sum, or which is otherwise privileged, disclosed to the Court on a confidential basis for the purposes of the settlement approval hearing.

2.

Interlocutory Application

18 April 2024

The following paragraphs of Annexure A, being the Unredacted Settlement Notice: [62], [66]–[67], [69]–[73], [76], [77] (but only the words between “the Independent Barrister” and “to an independent senior counsel”); Annexure A to the Settlement Notice.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) Group Members (upon undertaking to maintain confidentiality); (e) the Contradictor; (f) the Funder; and (g) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Until the expiry of the appeal period

3.

Affidavit of Christopher John Pagent

18 April 2024

Paragraphs [117], [121]–[122], [124]–[128], [131], [132] (but only the words between ‘the Independent Barrister’ and ‘to an independent senior counsel’).

The following parts of the Settlement Distribution Scheme contained at pages 165–195 of Confidential Exhibit CJP–1:

· the information contained between the definitions of “Group Member” and “Opt-Out Deadline” on page 172; and

· the following parts of Schedule 3 contained at pages 187–195:

· the words between “determination of the” and “to their claim” in definition of Statutory Declaration;

· cll 2.3, 2.4, 4, 5, 7;

· cl 8(c)(iv) (but only the words following ‘the Independent Barrister’s determination of the’); and

· cl 8(e) (but only the words between “the Independent Barrister in respect of” and “(Appeal Threshold)”.

4.

Affidavit of Christopher John Pagent

23 April 2024

The following paragraphs of Exhibit CJP–3, being the Unredacted Settlement Notice: [62], [66]–[67], [69]–[73], [76], [77] (but only the words between “the Independent Barrister’ and ‘to an independent senior counsel’); Annexure A to the Settlement Notice.

5.

Affidavit of Christopher John Pagent

26 June 2024

Paragraphs [87]–[89], [91]–[100], [104]–[107] (up to the table extract), [108] (but only the words between “the Independent Barrister of the” and “to an Independent Senior Counsel”) and [201] (but only following the words “Settlement Distribution Scheme”) to the end of [207].

The redactions indicated in Confidential Exhibit CJP–7 (Objections).

The following parts of the Settlement Distribution Scheme contained at pages 1–32 of Confidential Exhibit CJP–8:

· the information contained between the definitions of “Group Member” and “Opt-Out Deadline” on page 8;

· the following parts of Schedule 3 contained at pages 24–32:

· the words between “determination of the” and “to their claim” in definition of Statutory Declaration on page 26;

· cll 2.3, 2.4, 4, 5, 7;

· cl 8(c)(iv) (but only the words following “the Independent Barrister’s determination of the”); and

· cl 8(e) (but only the words between “the Independent Barrister in respect of” and “(Appeal Threshold)”.

5A.

Affidavit of Christopher John Pagent

26 June 2024

Paragraphs [68] (but only the information contained after the words “replicated below”), [75] (but only the information contained after the words “as follows”), [107] (but only the information contained after the words “as follows”). These paragraphs extract information from pages 165–175 of CJP-8.

The whole of Confidential Exhibit CJP–5 (Confidential Opinion).

The following parts of Confidential Exhibit CJP-6 (Costs Referee’s Reports):

· the third and fourth sentence of paragraph [64] on page 23; and

· the remainder of the second sentence following the words “For example,” in [65] on page 23.

Pages 165–175 and 366 of Confidential Exhibit CJP-8.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

10 years or until further order

Category 3 Information: Information which discloses: (i) sensitive aspects of the funding arrangements provided by the Funder; or (ii) privileged material provided to the Funder

6.

Affidavit of Christopher John Pagent

18 April 2024

The following parts of the Early Stage Funding Agreement contained in Confidential Exhibit CJP–1: key term (5), (6) and (7) on page 196.

The following parts of the Litigation Funding Agreement between the Applicant and the Funder contained in Confidential Exhibit CJP–1:

· the first definition after ‘definitions and interpretation’ on page 212;

· the sentences following ‘Item(k) of Schedule 2’ on page 212;

· the definitions following ‘Beneficiaries’ on page 213–214;

· the definition between ‘Business Day’ and ‘Claim’ on page 214;

· the description following the definition of ‘Claim Proceeds’ on page 214;

· the conclusion of the definition of ‘Early Stage Funding Amount’ following the words ‘means the amount of’ at page 216;

· the definition between ‘Loss’ and ‘Multiplicity Order’ on page 217;

· the sub points following ‘Tranche 1’, ‘Tranche 2’ and ‘Tranche 3’ on page 220;

· the words contained at the bottom of the header of the table on page 239;

· the information contained after ‘Option 1’ and ‘Option 2’ in schedule 2(d) on page 240;

· the particulars of schedule 2(e) on page 240;

· the particulars of schedule 2(f) on page 240;

· the particulars of schedule 2(g) on page 241;

· the particulars of schedule 2(i) on page 241;

· the information after ‘A/C Name’, ‘SWIFT CODE’, ‘BSB’ and ‘A/C’ under schedule 2(j) on page 241;

· the particulars of schedule 2(k) on page 241;

· the information contained following ‘the greater of’ in schedule 2(l) on page 241;

· clause 7.2.5 between the words ‘to’ and ‘set’ on page 251;

· schedule 6(1.1)(a)-(f) on page 254 after ‘the following basis:’; and

· schedule 7(1)-(4) on page 255 after ‘approval of any Settlement:’

The following parts of the Litigation Funding Agreement between the Funder and one of the Group Members contained in Confidential Exhibit CJP–1:

· the first definition after ‘definitions and interpretation’ on page 260;

· the sentences following ‘Item(k) of Schedule 2’ on page 260;

· the definitions following ‘Beneficiaries’ on page 261–262;

· the definition between ‘Business Day’ and ‘Claim’ on page 262;

· the description following the definition of ‘Claim Proceeds’ on page 262;

· the conclusion of the definition of ‘Early Stage Funding Amount’ following the words ‘means the amount of’ at page 264;

· the sub points following ‘Tranche 1’, ‘Tranche 2’ and ‘Tranche 3’ on page 268;

· the words contained at the bottom of the header of the table on page 287;

· the information contained after ‘Option 1’ and ‘Option 2’ in schedule 2(d) on page 288;

· the particulars of schedule 2(e) on page 288;

· the particulars of schedule 2(f) on page 288;

· the particulars of schedule 2(g) on page 289;

· the particulars of schedule 2(i) on page 289;

· the information after ‘A/C Name’, ‘SWIFT CODE’, ‘BSB’ and ‘A/C’ under schedule 2(j) on page 289;

· the particulars of schedule 2(k) on page 289;

· the information contained following ‘the greater of’ in schedule 2(l) on page 289;

· clause 7.2.5 between the words ‘to’ and ‘set’ on page 299;

· schedule 6(1.1)(a)-(f) on page 302 after ‘the following basis:’; and

· schedule 7(1)-(4) on page 303 after ‘approval of any Settlement:’

The following parts of the First Instance ATE Policy contained in Confidential Exhibit CJP–1:

· schedule 1(6.) following ‘Premium:’ on page 316; and

· schedule 1(7.) following ‘Limit:’ on page 316.

The following parts of the Appeal ATE Policy contained in Confidential Exhibit CJP–1:

· item 5 of the schedule between ‘Stage 1:’ and ‘($60,000)’ on page 334;

· item 5 of the schedule between ‘Stage 2:’ and ‘($87,500)’ on page 334;

· item 5 of the schedule under ‘Deferred Premium’ between ‘(i)’ and ‘(i.e. $165,000)’ on page 334;

· item 5 of the schedule under ‘Deferred Premium’ between ‘(ii)’ and ‘(i.e. $240,000)’ on page 334;

· item 6 of the schedule on page 334 after ‘Limit:’; and

· item 7 of the schedule on page 335 after ‘Participating Insurers’.

The following parts of the Affidavit of Christopher John Pagent sworn 18 April 2024:

· The figure following the word ‘up to’ in paragraph [46];

· The figure following the word ‘amount of’ in paragraph [52];

· The words following the words ‘of the claims’ in paragraph [65];

· The figure following the words ‘limit of’ in paragraph [67];

· The figure following the words ‘limit of’ in paragraph [72]; and

· Paragraphs [94] from the words ‘circumstances’ to the end of [96].

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Until the expiry of the appeal period

7.

Affidavit of Christopher John Pagent

18 April 2024

The following parts of the First Instance ATE Policy contained in Confidential Exhibit CJP–1: the remainder of page 317 following ‘Insurer Subscriptions’.

The following part of the Litica ATE Premium Invoice dated 20 May 2020 contained at page 322 of the Confidential Exhibit CJP–1: the information between ‘please make payments to:’ and ‘Thank you’.

The following part of the Litica ATE Premium Top Up Invoice dated 9 November 2023 contained at page 341 of the Confidential Exhibit CJP–1: the information following ‘please make payments to:’.

The following part of the Litica Invoice to The Judge dated 17 December 2020 contained at page 342 of the Confidential Exhibit CJP–1: the information between ‘please make payments to:’ and ‘Thank you’.

The following part of the PartnerRe Invoice to Augusta dated 18 March 2021 contained at page 345 of Confidential Exhibit CJP–1: the information following ‘Name and address of bank:’.

The following part of the Litica Invoice to The Judge dated 2021 contained at page 346 of the Confidential Exhibit CJP–1: the information between ‘please make payments to:’ and ‘Thank you’.

The following part of the Litica Invoice to Augusta dated 9 June 2022 contained at page 347 of the Confidential Exhibit CJP–1: the information between ‘please make payments to:’ and ‘Thank you’.

The following part of the Litica Invoice to Augusta dated 26 September 2022 contained at page 348 of the Confidential Exhibit CJP–1: the information between ‘please make payments to:’ and ‘Thank you’.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

10 years or until further order

8.

Affidavit of Christopher John Pagent

26 June 2024

Paragraphs [124] following the word “circumstances” to the end of [127].

Paragraph [130(i)] following the words “proposal whereby commission was” to the end of the sub-paragraph.

The following parts of Confidential Exhibit CJP-6 (Costs Assessors Reports):

· The words between “funding” and “to obtain advice” in [12] on page 12; and

· The penultimate sentence in [42] on page 17.

Pages 235–352 and 362–363 of Confidential Exhibit CJP–8.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Until expiry of the appeal period

9.

Affidavit of Chris Martin

4 July 2024

The following parts of the affidavit of Chris Martin affirmed on 4 July 2024:

· paragraph [23] (but only the words following “commencement of the proceedings and”);

· paragraph [27] (but only the words following “that included the following”);

· paragraphs [29] (but only the words following “greater of either” to the end of [30]);

· paragraph [34] (but only the figure between the words “amount of approximately” and “to fund the costs”);

· paragraph [36] (but only the words following “CEO of AVL, and me; and”)

· paragraph [42] (but only the figure between “contained a limit of” and “with an upfront premium”); and

· paragraph [43] (but only the figure between “with the limit of” and “with an upfront premium”).

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Until the expiry of the appeal period

10.

Exhibit CM-1

4 July 2024

The following parts of Exhibit CM–1:

· page 13 paragraph 29;

· pages 23–25 (until the words “Cristopher Symons QC”;

· pages 26 (under the words “Review Panel Legal Report) to 28;

· pages 55 to 66; and

· pages 68–83.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

10 years or until further order

11.

Exhibit CM-1

4 July 2024

The following parts of Exhibit CM–1:

· pages 1–7;

· page 14 paragraph 36 to page 18 (above the names at the bottom of the page);

· page 14 paragraph 35;

· pages 19 (under the words “Review Panel Economics Report”) to 21 (but only information above the words “The Review Member has provided a positive recommendation for funding this matter”); and

· page 85–92.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Until the expiry of the appeal period

12.

Exhibit CM-1

4 July 2024

The following parts of Exhibit CM–1:

· the redactions indicated on page 96;

· the redaction indicated on page 97;

· page 98 (but only the figure between the words “shall be distributed with” and “paid to the Funder” and the figure between the words “the Funder and” and “paid to the Insurer”); and

· page 106 (but only the redaction indicated on that page).

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Two years or until further order

13.

Funder’s Outline of Submissions

19 July 2024

The following paragraphs of the Funder’s Outline of Submissions:

· [14] (but only the figure between “seed funding of up to” and “for an opinion”);

· [15] (but only the words between “and contingent on” and “The relevant approvals”);

· [18] (but only the words following “in all the circumstances”);

· [22] (but only the words between “Resolution Sum” and “Augusta agreed”);

· [29] (but only the figure between the words “fee is equal to” and “of the aggregate of”, the figure between the words “Early Stage Funding Amount being” and “and the total amount” and the figure at the end of that paragraph);

· [35] (but only the figure between the words “with a limit of” and “from Partner Re Ireland DAC”);

· [36] (but only the figure between the words “with a limit of” and “The upfront premium”);

· [47] (but only the words between “being” and “the relevant Project Costs”);

· [51] (but only the words between “the alternative proposal was calculated as” and “Having regard to”, the words between “Having regard to” and “the alternative proposal”, and the words following “a commission based upon”);

· [52] (but only the figure between the words “approximately” and “The Funding Terms also referred to ATE premiums” and the figure between “total funding amount” and “There has therefore been no meaningful variation”);

· [55] (but only the figure between the words “in the vicinity of” and “The proceedings could not”);

· [56] (but only the words between “The Funding Terms noted” and “reflecting a significant period”);

· [57] (but only the words between “anticipated that the position on” and “Similarly, the funding application provided” and the figure between the words “deployed capital of approximately” and “prior to the first resolution”);

· [59] (but only following the words “the litigation was in respect of the”);

· [60] (but only following the words “heightened in the circumstances where the”);

· [61] (but only the figure between the words “to spend approximately” and “to fund the costs of the appeal”);

· [66] (but only the words between “which had a limit of” and “The ATE Appeal Policy” and the figure between “up to a limit of” and “Augusta seeks a deduction”); and

· [75] (but only the figure between the words “a sum of approximately” and “Further, Augusta expended”).

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Until the expiry of the appeal period

14.

Affidavit of Cigdem Kadayifci

23 August 2024

The following parts of the document annexed to the affidavit and entitled “Frequently asked questions”: From the words “free ride” to “as set out above” on page 196.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; (d) the Contradictor; (e) the Funder; and (f) the Funder’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

Until the expiry of the appeal period

Category 4 Information: Information which may be subject to a claim for confidentiality by Ms Mary Benton.

[Not used]

Category 5 Information: Information which discloses sensitive information regarding alternative funding proposals.

[Not pressed]

Category 6 Information: Information which discloses without prejudice communications authored by AMPFP, disclosed to the Court on a confidential basis for the purposes of the settlement approval hearing.

15.

Affidavit of Christopher John Pagent

26 June 2024

Paragraphs [34(a)–(g)], [35], and [54(a)–(b)].

The following parts of Confidential Exhibit CJP–8:

· page 33; and

· pages 82–164.

*Note that pages 34–81 of Confidential Exhibit CJP–8 were not in evidence.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; and (d) the Contradictor; (e) the Funder; (f) the Funder’s legal representatives; (g) the Respondent; and (h) the Respondent’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

10 years or until further order.

Category 7 Information: Information which discloses without prejudice communications authored by the Applicant, disclosed to the Court on a confidential basis for the purposes of the settlement approval hearing.

16.

Affidavit of Christopher John Pagent

26 June 2024

Paragraphs [69] and [73] (from the word “methodology”) to the end of [74], including footnote 1.

Pages 176–234 of Confidential Exhibit CJP–8.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; and (d) the Contradictor; (e) the Funder; (f) the Funder’s legal representatives; (g) the Respondent; and (h) the Respondent’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

10 years or until further order.

Category 8 Information: Personal information of group members (including addresses, email addresses etc).

17.

Affidavit of Christopher John Pagent

26 June 2024

Pages 368–376, 387 and 389–396 of Confidential Exhibit CJP–8.

The following persons: (a) the Court; (b) the Applicant; (c) the Applicant’s legal representatives; and (d) the Contradictor; (e) the Funder; (f) the Funder’s legal representatives; (g) the Respondent; and (h) the Respondent’s legal representatives.

These permitted disclosures are on the terms that none of these persons or entities disclose such material or any part of it to any person or entity other than those listed above.

10 years or until further order

Background

Background to the litigation

Doubtless the objectors will be bitterly disappointed. In these reasons, I set out in considerable detail why I am satisfied that in broad terms the settlement scheme should be approved. This is not because I am insensitive to the views of the objectors, that I disbelieve them or that I give their views little weight. I accept their accounts as truthful, their concerns valid and that each has properly put matters that are relevant upon this application. The principal reason why I have not acceded to their individual and collective position, is that I have objectively assessed all the material which I am satisfied provides a proper basis to exercise the statutory discretion to approve. BACKGROUND On 8 November 2021, Moshinsky J made an order fixing 28 January 2022 as the date by which a Group Member may opt out of the proceeding pursuant to s 33J(1) of the FCA Act. His Honour made consequential orders as to the form and content of the notice, its method of service and for public notification. A number of Group Members did opt out. On 31 August 2022, the parties unsuccessfully attended a mediation, at a point when each case had been substantially worked up. Thereafter, the trial proceeded for 21 days. His Honour pellucidly summarised the claims and his conclusions in the introductory part of his primary reasons at [3] – [22] which I gratefully reproduce (without original emphasis):The proceeding relates to changes made (or purportedly made) by AMPFP to the valuation methodology under its BOLR Policy on 8 August 2019. The BOLR Policy formed part of the contractual relationship between AMPFP and each financial planning practice in its network. As at August 2019, there were approximately 542 practices in the AMPFP network (described below). The BOLR Policy gave practices in the AMPFP network that wanted to exit the network the ability to sell back their register rights (defined below, but broadly the contractual relationships with customers including the right to commissions) to AMPFP on 12 months’ notice (or less in some cases). Under the BOLR Policy as it stood before the 8 August 2019 changes, subject to certain exceptions and qualifications, the register rights were to be valued on the basis of a multiple of 4x ongoing revenue (i.e. ongoing revenue received by the practice in the prior 12 months) and the practice would be paid that amount by AMPFP.On 8 August 2019, AMPFP amended (or purported to amend) the valuation methodology under the BOLR Policy (the 8 August 2019 Changes) with immediate effect. The changes were broadly as follows:(a) changing the multiple for the purposes of the BOLR Policy from 4x to 2.5x in respect of ongoing revenue other than grandfathered commission revenue; and(b) changing the multiple for grandfathered commission revenue:(i) initially, from 4x to 1.42x; and(ii) then, reducing by 0.8333 per month (referred to as a “glide path”) from 1 September 2019, such that the multiple would be zero by 1 January 2021.The changes to the multiples were applied by AMPFP not only to practices that submitted a BOLR application after 8 August 2019, but also to practices that had submitted a BOLR application before 8 August 2019 with an exercise date after 8 August 2019. Under the terms of the BOLR Policy, those practices could not withdraw their application once it had been submitted unless AMPFP consented.The central issue in this proceeding is whether the 8 August 2019 Changes were effective. The BOLR Policy had been in place for many years, and had been revised from time to time. The latest version of the policy as at 8 August 2019 was the version of the policy that commenced on 1 June 2017 (the 2017 BOLR Policy). That version of the policy contained a term relating to amendments that had been agreed between AMPFP and the AMP Financial Planners Association Ltd (ampfpa), which was an organisation representing financial planning practices in the AMPFP network (described below). The amendment term (on page 5 of the policy) was as follows:Changes to this policyThe AMP Financial Planners Association Ltd Board (ampfpa) and AMPFP have agreed in writing to the terms of this policy effective 1 June 2017.-Unless a shorter period of notice is agreed to by the ampfpa, AMPFP will give 13 months’ notice of a change to the valuation methodology for registers and to any other change having a materially adverse financial or other significant effect on a practice.-Subject to the above, AMPFP may make any other changes to this policy following consultation with the ampfpa.-AMPFP has the right to make any change to this policy should legislation, economic or product changes render any part of this policy inappropriate following consultation with the ampfpa. In particular, where AMPFP believes that any provision contained in this policy will, or may, cause it to breach or be subject to a penalty under any laws.-The Buyer of last resort terms that apply are those terms in force on the Buyer of last resort exercise date or the date the practice surrenders its AR [Authorised Representative] Agreement, whichever is the later.I will refer to the third indented paragraph, which refers to “legislation, economic or product” changes, as the LEP Provision. (The paragraph was referred to as the “LEP Exception” in Equity’s submissions and as the “LEP Provision” in AMPFP’s submissions. Whether the paragraph constitutes an exception forms part of an issue in the proceeding, namely the issue of onus. I will therefore adopt the neutral expression, “LEP Provision”.)Equity contends that the 8 August 2019 Changes were not authorised by the LEP Provision (or otherwise authorised by the amendment term). In summary, Equity contends that:(a) AMPFP did not consult with ampfpa in relation to the changes as required by the LEP Provision and the Master Terms (referred to below);(b) AMPFP did not identify the economic or legislation changes it was relying on in making the changes, and did not state how these rendered the policy inappropriate;(c) There was no “economic change” or “legislation change” within the meaning of the LEP Provision;(d) If (contrary to the above) there was an economic or legislation change, it did not render any part of the policy “inappropriate” within the meaning of the LEP Provision; and(e) If (contrary to the above) there was an economic or legislation change that rendered a part of the policy inappropriate, the changes to the multiples were not reasonably necessary to address that circumstance (Equity contends that this is a requirement of the LEP Provision, properly interpreted).Accordingly, Equity contends that the 8 August 2019 Changes were ineffective and that AMPFP acted in breach of contract in putting forward BOLR valuations based on those changes. Equity seeks a declaration that the changes were ineffective and claims damages for loss and damage. In the alternative, Equity claims that AMPFP acted in breach of a contractual obligation of good faith in relation to the changes. In the further alternative, Equity contends that AMPFP engaged in unconscionable conduct within the meaning of s 21 of the Australian Consumer Law, being Sch 2 to the Competition and Consumer Act 2010(Cth) (the Australian Consumer Law), in relation to the changes. Further, Equity contends that AMPFP engaged in conduct that was misleading or deceptive, or likely to mislead or deceive, in connection with the changes in contravention of s 18 of the Australian Consumer Law.In response, AMPFP contends that the 8 August 2019 Changes were authorised by the LEP Provision (and were effective immediately). In summary, AMPFP contends that:(a) while there was a contractual obligation upon AMPFP to consult (within the meaning of cl 1.4 of the Master Terms) with ampfpa, the obligation was not “jurisdictional”; that is, a breach of the obligation does not have the effect that the changes are ineffective; the breach merely sounds in damages for the loss of opportunity to consult, but this results in an award of only nominal damages;(b) In any event, on the facts, AMPFP did consult (within the meaning of cl 1.4 of the Master Terms) with ampfpa in relation to the changes;(c) It is not a requirement of the LEP Provision that AMPFP identify the economic or legislation change that it relies on; nor is it a requirement that it state how these render the policy inappropriate;(d) There was an “economic change” that rendered the policy inappropriate, namely either:(i) A sustained and quantifiable decrease in the market value of register rights linked to ongoing revenue; or(ii) a material change in the supply of and demand for financial advice services and practices;(e) Further, in relation to the changes to grandfathered commission revenue, there was a “legislation change” that rendered the policy inappropriate; and(f) The changes that were made were responsive to the economic and/or legislation changes (this being the relevant requirement, on AMPFP’s interpretation of the LEP Provision).In the alternative, AMPFP contends that the 8 August 2019 Changes were effective 13 months later, that is, on 8 September 2020.The hearing of this proceeding in October and November 2022 involved the trial of Equity’s claim against AMPFP on all issues of liability and the amount of any damages. Equity did not enter into a buy-back agreement with AMPFP and still holds its register rights.The hearing also involved the trial of the claim of one sample Group Member, WealthStone Pty Ltd (WealthStone), on all issues of liability and the amount of any damages. Unlike Equity, WealthStone did enter into a buy-back agreement with AMPFP. That agreement contained a release in favour of AMPFP. AMPFP contends that the release defeats WealthStone’s claim against it. In response, Equity Financial contends that:(a) The condition precedent to the operation of the release – the payment of the BOLR benefit (properly calculated) – has not been satisfied;(b) The release is void under s 23 of the Australian Consumer Law, which applies to unfair terms of small business contracts; and(c) AMPFP’s conduct in procuring the release was, in all the circumstances, unconscionable within the meaning of s 21 of the Australian Consumer Law.I was informed by AMPFP that approximately 135 Group Members have signed buy-back agreements with AMPFP. About 120 of those agreements contain releases, but they are not all in the same form.In summary, for the reasons that follow, I have concluded as follows:(a) the 8 August 2019 Changes were not authorised by the LEP Provision on the basis of AMPFP’s first alternative economic change contention;(b) the 8 August 2019 Changes were not authorised by the LEP Provision on the basis of AMPFP’s second alternative economic change contention;(c) the changes to the multiple for grandfathered commission revenue (which were part of the 8 August 2019 Changes) cannot be supported on the basis of a “legislation change”;(d) the requirement to consult (within the meaning of cl 1.4 of the Master Terms) is a precondition to the effectiveness of the change;(e) AMPFP failed to consult within the meaning of cl 1.4 of the Master Terms in relation to the proposed changes; and(f)It is unnecessary to determine whether AMPFP breached a contractual obligation of good faith.It follows from the above that the 8 August 2019 Changes (with immediate effect) were not authorised by the LEP Provision and were ineffective.Insofar as AMPFP contends, in the alternative, that the 8 August 2019 Changes were effective 13 months later (on 8 September 2020), I reject that contention.In light of the above conclusions, it is unnecessary to determine whether AMPFP engaged in unconscionable conduct in relation to the 8 August 2019 Changes.It is not necessary to resolve the misleading or deceptive conduct claim to determine the individual claims of Equity or WealthStone, and I therefore prefer not to do so at this stage.In relation to Equity’s claim, I am satisfied that Equity has suffered loss and damage as a result of AMPFP’s breach of contract, and is entitled to damages in the sum of $813,560 (subject to the possible need to adjust this figure as discussed in [675] below).In relation to WealthStone’s claim, I have concluded in summary that:(a) the condition precedent to the operation of the release has been satisfied;(b) the release is not void under s 23 of the Australian Consumer Law; and(c) AMPFP’s conduct in procuring the release was, in all the circumstances, unconscionable.WealthStone is entitled to an order declaring the release void to the extent that it would preclude its claims in this proceeding. Further, WealthStone is entitled to damages in the sum of $115,533.51 (subject to the possible need to adjust this figure as discussed in [719] below).

Evidence

Evidence Before The Court

On any view, the trial was a hard-fought contest and the appeal, if it proceeds, will be likewise litigated.EVIDENCE AND SUBMISSIONS RELIED ON Equity Financial primarily relies on:(1)Affidavits of Christopher Pagent, solicitor and partner of Corrs who has primary carriage of the proceeding, made on 18 and 23 April and 26 June and 30 August 2024, portions of which are redacted in accordance with confidentiality orders;(2)Counsel’s submissions of 5 July 2024;(3)Counsel’s Confidential Opinion on the settlement application of 25 June 2024. The Funder relies on:(1)An affidavit of Christopher Martin, an investment manager employed by Augusta Ventures Ltd (the holding company of the Funder) made on 4 July 2024. Mr Martin is employed in the London office of the holding company;(2)An affidavit of Thomas Riddell, the Funder’s solicitor, made on 19 July 2024; and(3)Counsel’s submissions of 19 July and 23 August 2024. AMPFP relies on counsel’s submissions of 23 August 2024. The Contradictor, Mr Kirkwood SC with Mr Nanlohy, has provided written submissions of 9 August 2024. The Costs Referee, Ms Harris has provided her referee reports of 31 May and 19 June 2024. Three objecting parties have filed interlocutory applications, supported by affidavits. Pinnacle Financial and Investment Services Pty Ltd by interlocutory application dated 23 August 2024, seeks leave to be heard together with orders that it not be bound by or otherwise affected by the Settlement Deed, but otherwise be bound by any settlement of the proceeding that is approved by the Court and, for the avoidance of doubt, that it remains bound by orders 1 and 2 made on 29 August 2023 on the common questions. Entire Financial Solutions Pty Ltd by interlocutory application dated 2 August 2024, seeks leave to bring the application and orders that it is not bound or affected by the Settlement Deed, any settlement Distribution Scheme that is approved by the Court or any orders approving the settlement of this proceeding. In the alternative it seeks orders that it “be opted out” of this proceeding. Investment, Retirement, Insurance & Superannuation Pty Ltd (IRIS) by interlocutory application dated 23 August 2024, seeks leave to be heard and to bring the application together with orders that it not be bound by any settlement of the proceeding as approved by the Court, not be bound by the Settlement Deed, not be bound by any settlement Distribution Scheme approved by the Court but, for the avoidance of doubt, that it remains bound by orders 1 and 2 made on 29 August 2023 on the common questions. In the alternative it seeks an order that the time to file an opt-out notice be extended to a date to be fixed and that, upon such filing, that it ceases to be a Group Member and thereby not be bound by any settlement of the proceeding. Those interlocutory applications were not ultimately pressed, for reasons that I explain relating to the scope of the release clause in the Settlement Deed. All affidavits were formally read without objection and no application was made for leave to cross-examine any deponent.

Decision

Reasons for decision

Framing orders to accommodate these categories is complex, and determining which documents may be publicly released and when is also complex. The latter task should not be left to the administrative staff of the Court. I will order the applicant to prepare and file electronic bundles of redacted documents. One will apply to the expiry of the appeal period and the other from it.CONCLUSION For these reasons, I have determined that orders should be made approving the settlement, with certain modifications, and that confidentiality orders are appropriate.

Ratio Decidendi

Legal Principle Established

The interlocutory application for settlement approval gave notice that Equity Financial intends to apply for a funding equalisation order to apportion the cost of the Funder’s entitlements pursuant to the litigation funding agreements equally as between the Group Members, regardless of whether a Group Member entered into a funding agreement.CONSIDERATION In what follows, I express some of my findings and reasons at a level of generality so as not to disclose material that is subject to confidentiality orders. MATTERS RAISED IN THE OBJECTIONS In assessing a settlement, the views of objecting Group Members “provide a convenient focus for the Court” in the identification “of any features of a settlement that are obviously unreasonable or unfair: Fowkes at [38] per Lee J. In this proceeding, the objectors are all people, some with long-standing commercial and professional relationships with AMPFP, either individually or through corporate structures. In summary, 92 notices of objection have been provided from 86 Group Members. A convenient summary of the objections is contained in the third affidavit made by Christopher Pagent, which I am satisfied is accurate and which I adopt: I have considered the terms of each objection. Many are deeply personal: some attach documents in support of a claim that the likely amount to be received pursuant to the Distribution Scheme is less than the objector’s “contractual entitlement”. Disappointment, grievance and personal suffering are common themes. For example, one objector in part says:This entire process has seen AMP duck and weave their way around their responsibility. This responsibility sits at a professional, ethical, and human level and I believe AMP have missed the mark in relation to the settlement.We have heard from AMP executives regarding this settlement and how it is a material step forward in restoring the relationship between the adviser network and licensee, yet this offer comes with the bitter pill that it is AMP walking away unaccountable for the irreplaceable losses, grief, distress, anger, and pain they have caused even though the Courts have already found them guilty.We all know stories where advisers, businesses, families, and other relationships have fallen or been torn apart while the corporate juggernaut, being AMP, continues to forge ahead seemingly oblivious or undeterred by these ramifications.In my opinion, the offer made continues to support this view, as it does not adequately compensate those impacted on any of these levels. In contrast, the Contradictor does not accept that deduction of the claimed ATE insurance premiums is fair and reasonable and with some force submits that I should not approve of it. In forming that view, the Contradictor accepts that a range of approaches have been adopted by this Court to these claims as summarised by Murphy J in Ghee v BT Funds ManagementLtd [2023] FCA 1553 at [147] – [152]. The Contradictor further accepts that it is relevant to consider the number of Group Members who entered into litigation funding agreements and accepted that this item would be included as a Project Cost and that the Funder has agreed, despite its contractual entitlement, not to seek reimbursement of the deferred ATE premiums.